Comment on

• Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

  Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams R, Atkins M. Naoumov NV, et al. J Hepatol. 2001 Jun;34(6):888-94. doi: 10.1016/s0168-8278(01)00039-3. J Hepatol. 2001. PMID: 11451173 Clinical Trial.
• Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.

  Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW. Rosenau J, et al. J Hepatol. 2001 Jun;34(6):895-902. doi: 10.1016/s0168-8278(01)00089-7. J Hepatol. 2001. PMID: 11451174
• Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.

  Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M. Marzano A, et al. J Hepatol. 2001 Jun;34(6):903-10. doi: 10.1016/s0168-8278(01)00080-0. J Hepatol. 2001. PMID: 11451175